These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 23597930

  • 21. The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer.
    Flamen P, Lerut A, Van Cutsem E, Cambier JP, Maes A, De Wever W, Peeters M, De Leyn P, Van Raemdonck D, Mortelmans L.
    J Thorac Cardiovasc Surg; 2000 Dec; 120(6):1085-92. PubMed ID: 11088030
    [Abstract] [Full Text] [Related]

  • 22. The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer.
    Cerfolio RJ, Ojha B, Bryant AS, Raghuveer V, Mountz JM, Bartolucci AA.
    Ann Thorac Surg; 2004 Sep; 78(3):1017-23; discussion 1017-23. PubMed ID: 15337041
    [Abstract] [Full Text] [Related]

  • 23. Regional nodal staging with 18F-FDG PET-CT in non-small cell lung cancer: Additional diagnostic value of CT attenuation and dual-time-point imaging.
    Li M, Wu N, Liu Y, Zheng R, Liang Y, Zhang W, Zhao P.
    Eur J Radiol; 2012 Aug; 81(8):1886-90. PubMed ID: 21511421
    [Abstract] [Full Text] [Related]

  • 24. Non-small cell lung cancer: whole-body MR examination for M-stage assessment--utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT.
    Ohno Y, Koyama H, Onishi Y, Takenaka D, Nogami M, Yoshikawa T, Matsumoto S, Kotani Y, Sugimura K.
    Radiology; 2008 Aug; 248(2):643-54. PubMed ID: 18539889
    [Abstract] [Full Text] [Related]

  • 25. The importance of 18F-FDG PET/CT, CT and X-rays in detecting primary stage III A lung cancer and the incidence of extra thoracic metastases.
    Sharma R, Tripathi M, D'Souza M, Jaimini A, Saw SK, Singh D, Mishra A, Mondal A.
    Hell J Nucl Med; 2009 Aug; 12(1):22-5. PubMed ID: 19330177
    [Abstract] [Full Text] [Related]

  • 26. FDG-PET imaging for lymph node staging and pathologic tumor response after neoadjuvant treatment of non-small cell lung cancer.
    Ohtsuka T, Nomori H, Ebihara A, Watanabe K, Kaji M, Naruke T, Suemasu K, Uno K.
    Ann Thorac Cardiovasc Surg; 2006 Apr; 12(2):89-94. PubMed ID: 16702929
    [Abstract] [Full Text] [Related]

  • 27. "One-stop-shop" staging: should we prefer FDG-PET/CT or MRI for the detection of bone metastases?
    Heusner T, Gölitz P, Hamami M, Eberhardt W, Esser S, Forsting M, Bockisch A, Antoch G.
    Eur J Radiol; 2011 Jun; 78(3):430-5. PubMed ID: 19945240
    [Abstract] [Full Text] [Related]

  • 28. Evaluation of gross tumor size using CT, 18F-FDG PET, integrated 18F-FDG PET/CT and pathological analysis in non-small cell lung cancer.
    Yu HM, Liu YF, Hou M, Liu J, Li XN, Yu JM.
    Eur J Radiol; 2009 Oct; 72(1):104-13. PubMed ID: 18640802
    [Abstract] [Full Text] [Related]

  • 29. Can (18)F-FDG PET/CT scan change treatment planning and be prognostic in recurrent colorectal carcinoma? A prospective and follow-up study.
    Artiko V, Odalovic S, Sobic-Saranovic D, Petrovic M, Stojiljkovic M, Petrovic N, Kozarevic N, Grozdic-Milojevic I, Obradovic V.
    Hell J Nucl Med; 2015 Oct; 18(1):35-41. PubMed ID: 25840571
    [Abstract] [Full Text] [Related]

  • 30. PET/CT using 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management.
    Keidar Z, Haim N, Guralnik L, Wollner M, Bar-Shalom R, Ben-Nun A, Israel O.
    J Nucl Med; 2004 Oct; 45(10):1640-6. PubMed ID: 15471827
    [Abstract] [Full Text] [Related]

  • 31. Role of FDG PET-CT in asymptomatic epithelial ovarian cancer with rising serum CA-125: a pilot study.
    Ghosh J, Thulkar S, Kumar R, Malhotra A, Kumar A, Kumar L.
    Natl Med J India; 2013 Oct; 26(6):327-31. PubMed ID: 25073988
    [Abstract] [Full Text] [Related]

  • 32. CA 15.3 measurements for separating FDG PET/CT positive from negative findings in breast carcinoma recurrence. Factors influencing the area under the ROC curve.
    Kruse V, Van de Wiele C, Borms M, Maes A, Pottel H, Sathekge M, Cocquyt V.
    Nuklearmedizin; 2014 Aug 06; 53(4):131-8. PubMed ID: 25100557
    [Abstract] [Full Text] [Related]

  • 33. Evaluation for local failure by 18F-FDG PET/CT in comparison with CT findings after stereotactic body radiotherapy (SBRT) for localized non-small-cell lung cancer.
    Takeda A, Kunieda E, Fujii H, Yokosuka N, Aoki Y, Oooka Y, Oku Y, Ohashi T, Sanuki N, Mizuno T, Ozawa Y.
    Lung Cancer; 2013 Mar 06; 79(3):248-53. PubMed ID: 23246123
    [Abstract] [Full Text] [Related]

  • 34. 18F-fluorodeoxyglucose positron emission tomography/computed tomography is useful in postoperative follow-up of asymptomatic non-small-cell lung cancer patients.
    Toba H, Sakiyama S, Otsuka H, Kawakami Y, Takizawa H, Kenzaki K, Kondo K, Tangoku A.
    Interact Cardiovasc Thorac Surg; 2012 Nov 06; 15(5):859-64. PubMed ID: 22914804
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Assessing the usefulness of 18F-fluorodeoxyglucose PET-CT scan after stereotactic body radiotherapy for early-stage non-small cell lung cancer.
    Pastis NJ, Greer TJ, Tanner NT, Wahlquist AE, Gordon LL, Sharma AK, Koch NC, Silvestri GA.
    Chest; 2014 Aug 06; 146(2):406-411. PubMed ID: 24577678
    [Abstract] [Full Text] [Related]

  • 39. Assessment of recurrence of non-small cell lung cancer after therapy using CT and Integrated PET/CT.
    Opoka L, Szołkowska M, Podgajny Z, Kunikowska J, Barańska I, Błasińska-Przerwa K, Jakubowska L, Rudziński P, Bestry I, Roszkowski-Śliż K.
    Pneumonol Alergol Pol; 2013 Aug 06; 81(3):214-20. PubMed ID: 23609428
    [Abstract] [Full Text] [Related]

  • 40. Timing of fluorodeoxyglucose positron emission tomography maximum standardized uptake value for diagnosis of local recurrence of non-small cell lung cancer after stereotactic body radiation therapy.
    Tan D, Gill S, Loh N.
    Cancer Med; 2020 Oct 06; 9(20):7469-7476. PubMed ID: 32846054
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.